Smartleaf Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Smartleaf Asset Management's GLUE Position: Q3 2026 in Review
Smartleaf Asset Management increased its Monte Rosa Therapeutics (GLUE) stake by 54% in Q3 2026, buying an estimated $343 and bringing the position to 57 shares worth $669. The position accounts for ﹤0.01% of the portfolio, ranked #3284.
Smartleaf Asset Management first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $884 in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Smartleaf Asset Management held 57 shares of Monte Rosa Therapeutics worth $669 as of Q3 2026.
- Smartleaf Asset Management bought 20 Monte Rosa Therapeutics shares in Q3 2026, an estimated $343.
- Monte Rosa Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3284 holding.
- Smartleaf Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Smartleaf Asset Management's Monte Rosa Therapeutics position peaked at $884 in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.